



Review

# The Interplay between Host Innate Immunity and Hepatitis E Virus

Yang Li <sup>1,2</sup>, Changbo Qu <sup>2</sup>, Peifa Yu <sup>2</sup>, Xumin Ou <sup>2</sup>, Qiuwei Pan <sup>1,2,\*</sup> and Wenshi Wang <sup>2,3,\*</sup>

<sup>1</sup> China-Malaysia National Joint Laboratory, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China; y.li.2@erasmusmc.nl

<sup>2</sup> Postgraduate School Molecular Medicine, Erasmus MC-University Medical Center, 3015 CN Rotterdam, The Netherlands; c.qu@erasmusmc.nl (C.Q.); p.yu@erasmusmc.nl (P.Y.); x.ou@erasmusmc.nl (X.O.)

<sup>3</sup> Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, 69120 Heidelberg, Germany

\* Correspondence: q.pan@erasmusmc.nl (Q.P.); w.wang.2@erasmusmc.nl (W.W.)

Received: 19 April 2019; Accepted: 6 June 2019; Published: 11 June 2019



**Abstract:** Hepatitis E virus (HEV) infection represents an emerging global health issue, whereas the clinical outcomes vary dramatically among different populations. The host innate immune system provides a first-line defense against the infection, but dysregulation may partially contribute to severe pathogenesis. A growing body of evidence has indicated the active response of the host innate immunity to HEV infection both in experimental models and in patients. In turn, HEV has developed sophisticated strategies to counteract the host immune system. In this review, we aim to comprehensively decipher the processes of pathogen recognition, interferon, and inflammatory responses, and the involvement of innate immune cells in HEV infection. We further discuss their implications in understanding the pathogenic mechanisms and developing antiviral therapies.

**Keywords:** Innate immunity; Hepatitis E virus; Interferon; Inflammation

## 1. Introduction

Hepatitis E virus (HEV) represents an emerging zoonotic pathogen imposing a growing health burden [1]. Globally, it has been estimated that 2.3 billion people have possibly encountered this virus, whereas the clinical outcomes vary dramatically among different populations [2]. In general, HEV infection is self-limiting, but can cause severe diseases in special patients. Acute infection in pregnant women bears high risk of triggering acute liver failure (ALF), leading to a high mortality rate, and most of these patients are from resource-limited regions infected with the non-zoonotic genotype 1 HEV [3,4]. In European countries, chronic infection has been widely described in immunocompromised patients, in particular, organ transplantation patients [5,6]. Chronic infection is mainly caused by the zoonotic genotypes 3 [5] and 4 [7]. Evidently, the host immune responses are critical in determining the distinct outcomes of HEV infection among the different individuals [8].

The host immune system, including innate and adaptive immunity, essentially protects against pathogen invasions, but over-activation or dysregulation may cause pathogenesis [9]. As the first line of host defense, the innate immune system rapidly, but non-specifically, responds to viral infections. Upon sensing the pathogen, the host produces a large spectrum of cytokines and chemokines, in particular, the antiviral interferons (IFNs). IFNs trigger the transcription of hundreds of interferon-stimulated genes (ISGs), as the ultimate antiviral factors to combat the infection or further regulate immune response. The pro-inflammatory cytokines and chemokines induce an inflammatory response and recruit other immune cells to coordinately orchestrate the antiviral status [9,10].

The quantity and quality of host immune responses essentially determine the infection course of HEV and the clinical outcome in patients. The response of host innate immunity to HEV infection has been widely observed in experimental models and in patients. In turn, HEV has been reported to evade host immunity through multiple sophisticated strategies. Here, we aim to in depth decipher the dynamic interplay between HEV and the host innate immunity.

## 2. Innate Immune Response to HEV Infection


### 2.1. Recognition by Pathogen-Recognition Receptors in HEV Host Cells

The innate immunity controls and restricts the spread of infection immediately after contacting with the pathogen. The innate immune system detects viral infection through the recognition of pathogen-associated molecular patterns (PAMPs) by pathogen-recognition receptors (PRRs). These PAMPs are specifically present in the pathogen or generated during infection [11,12]. There are three distinct classes of PRRs in recognizing viruses, including toll like receptors (TLRs), retinoic-acid-inducible gene I (RIG-I)-like receptors (RLRs), and NOD-like receptors (NLRs). TLRs sense virus on cell membrane or in endosomes, whereas RLRs and NLRs detect virus in cytoplasm.

TLRs are cell membrane-associated PRRs that are present on the cell surface or in the endosomes. They can recognize viral nucleic acids or other components to trigger the production of IFNs and other cytokines through different cascades, such as TLR3 recognizing dsRNA, whereas TLR7/8 recognizes ssRNA [13–15]. TLRs are abundantly expressed in hepatocytes, the primary target cells of HEV. TLRs serve as principal elements of the hepatic immune system that defend infections in general. Both TLR3 and TLR7 signaling have been found to recognize hepatitis B (HBV) and C (HCV) virus to trigger an innate antiviral response [16–19]. In cell culture models, overexpression of TLR3 inhibits HEV replication. Consistently, blocking the TBK1/IKK $\epsilon$  complex, the downstream molecules of TLR3 enhances HEV replication [20] (Figure 1). TLR signaling is roughly divided into two distinct pathways based on the usage of either MyD88 or TRIF adaptor molecules. Suppression of both MyD88 and TRIF inhibits TLR3-mediated IL-8 induction by HEV [21]. MyD88 deficiency attenuates the induction of IL-6 and RANTES by HEV. However, there is no effect of TRIF knockdown on IL-6 levels, suggesting that TLR2 and TLR4 are also involved in sensing HEV [21]. Interestingly, ORF3 of HEV augments the poly (I:C)-induced TLR3 pathway and enhances TBK1-mediated IFN- $\beta$  expression [22]. In pregnant women infected with HEV, the expression levels of TLR2, TLR3, TLR4, and IFN- $\gamma$  are significantly higher in those who recovered from acute infection compared to the ones that developed ALF [23]. Consistently, down-regulation of TLR3 and TLR7, as well as TLR downstream molecules, has been observed in another cohort of HEV infected pregnant women with ALF [3]. Thus, both in vitro and in vivo data support the prominent role of TLRs in recognizing HEV and triggering antiviral and inflammatory responses.

RLRs include melanoma differentiation associated gene 5 (MDA5), retinoic acid-inducible gene (RIG-I), and laboratory of genetics and physiology gene 2 (LGP2), and all are located in cytoplasm [24,25]. Short dsRNA and 5'-triphosphate RNA are ligands for RIG-I, while MDA5 mainly recognizes long dsRNA [24,26]. Both MDA5 and RIG-I consist of two caspase activation recruitment domains (CARDs) at their N-terminal domains, a helicase domain, and a C-terminal domain. Upon binding to foreign RNA, the CARD domain of MDA5 and RIG-I recruits mitochondrial antiviral signaling (MAVS, also known as IPS-1, VISA, or Cardif) [27–30] to activate IRF3/7 and NF- $\kappa$ B, leading to the production of IFNs and other cytokines. In hepatocytes, RIG-I recognizes the 5'- $\epsilon$  region of HBV pgRNA and the polyuridine motif of HCV genome 3' non-translated region, whereas HCV replicative dsRNA is recognized by MDA5 to initiate IFN-related antiviral responses [31–35]. However, whether MDA5 and RIG-I represent bone fide sensors for HEV remains to be clarified, although infection of HEV has been found to upregulate the expression of both genes. Earlier studies have suggested that MDA5 and RIG-I may recognize HEV RNA in human hepatic cells (Figure 1) [20,36]. However, a recent study has demonstrated that loss of MDA5 or/and RIG-I in mouse embryonic fibroblasts does not affect HEV

RNA-induced IFN response [37]. Whether this discrepancy is attributed to the different cell types remains to be further investigated.



**Figure 1.** The interplay of the interferon (IFN) antiviral signaling and HEV. Upon infection, HEV is recognized by the host pattern-recognition receptors, including MDA5, RIG-I, TLR3, and TLR7. This triggers their downstream cascades, including IRF3 and NF- $\kappa$ B, leading to the production of IFNs. Subsequently, IFN binds to the receptors and results in phosphorylation of STAT1 and STAT2. Phosphorylated STAT1 and STAT2 form a complex with IRF9 (ISGF3). This complex translocates to nucleus and binds to IFN-stimulated response element (ISRE) to induce the transcription of antiviral IFN-stimulated genes (ISGs). RIG-I and MDA5 have been identified to inhibit HEV replication. On the other hand, HEV has evolved strategies to evade host IFN response. ORF1 inhibits phosphorylation of STAT1 and IRF3 as well as deubiquitination of RIG-I. ORF2 inhibits activation of NF- $\kappa$ B. ORF3 blocks phosphorylation of STAT1 and IRF3, but also has been reported to induce IFN production through increased activation of RIG-I. a, b, c, d, e, f, g, and h indicate the important interactions between viral proteins and host factors.

Besides hepatitis, HEV infection is also associated with a broad spectrum of extra-hepatic manifestations in patients including neurological diseases [38–40], renal injuries [41], and acute pancreatitis [42,43]. In experimental models, the direct infection of non-hepatic cell types, including neurons, brain microvascular cells, and kidney cells, has been demonstrated [44–46]. In pregnant women, HEV can also result in severe placental diseases, and the direct infection has been recently demonstrated at the human maternal–fetal interface. Genotype 1 HEV efficiently replicates in the tissue explants of decidua basalis and fetal placenta and stromal cells, and importantly triggers the production of a panel of cytokines and chemokines [47]. Thus, the innate sensors in these non-hepatic cells are also likely able to recognize HEV but require future research to further clarify.

## 2.2. Innate Immune Cells on HEV Infection

A viral infection rapidly recruits innate immune cells such as natural killer (NK) and natural killer T (NKT) cells to the site of infection [48]. Upon recognition, NK cells secrete cytokines including IFN- $\gamma$  and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) to modulate antiviral immune responses [49]. NK and NKT cells constitute a major fraction of lymphocytes in the liver, and they are particularly important in the pathogenesis of viral hepatitis [50]. Both cell types play a critical role in the induction of liver cell injury during acute hepatitis B and C [51,52]. It has been suggested that NK cells may also mediate

immune response to HEV infection [53]. In patients with acute hepatitis E, the percentages of NK and NKT cells among peripheral blood mononuclear cells (PBMCs) are significantly lower, whereas the proportions of activated NK and NKT cells are higher compared with those in uninfected controls [54]. This is consistent with another report that HEV infection is particularly severe in pregnant women with a decrease in NK cell activity [55]. The decreased percentages of NK and NKT cells in circulation may be explained by increased migration of these activated cells to the liver or apoptosis induction because of activation. However, CD56 (natural killer cells) and Granzyme B (activated NK cell marker) are significantly increased in biopsies from ALF patients caused by hepatitis E, compared with normal livers [56], and CD69 (activated NK cell marker) expression is increased in immunocompromised organ transplant patients acutely infected with HEV [57]. This might be associated with enhanced cytotoxic activity [58]. Mast cells constitute another major sensory arm of the innate immune system. In Mongolian gerbils, HEV infection increases the number, but also the activation, of mast cells in the liver and small intestine [59].

### 2.3. IFN and Inflammatory Responses to HEV Infection

Upon recognition of PAMP, PRRs activate intracellular signaling cascades, ultimately triggering IFN and inflammatory responses. Among the three types of IFNs, type I and III IFNs activate the same pathway involving the signal transducer and activator of transcription 1 (STAT1) and signal transducer and activator of transcription 2 (STAT2) [60]. Phosphorylated STAT1 and STAT2 form a complex with IRF9, also known as IFN-stimulated gene factor 3 (ISGF3). ISGF3 translocates into the nucleus and binds to IFN-stimulated response element (ISRE) to activate the transcription of hundreds of ISGs [61,62]. ISGs are the genetic effectors coordinating antiviral and immunomodulatory activities [9,10,63].

In cell culture, inoculation with infectious HEV particles activates type III, but not type I IFN response, with transcription of multiple ISGs. This requires MAVS or MDA5, and to a lesser extent RIG-I [64]. The low infectivity of HEV in cell culture models often fails to adequately mimic the robust viral replication in patients, because the viral load in patient blood can reach up to  $10^7$  copies/mL [65]. A subsequent study delivering *in vitro* generated HEV genomic RNA into cells has demonstrated a robust induction of type I IFN response. This is independent of MDA5, RIG-I, and MAVS, but requires the downstream transcription factors IRF3/7 [37]. As discussed, the role of MDA5 and RIG-I in sensing HEV remains not fully clear [20,36,37], but their anti-HEV activities as ISGs have been convincingly demonstrated. By profiling the known antiviral ISGs, MDA5, RIG-I, and IRF1 have been identified as the most potent anti-HEV effectors [66]. RIG-I inhibits HEV replication by further induction of antiviral ISGs, partially through the JAK-STAT cascade, but without requirement of IFN production [66]. IRF1 inhibits HEV replication through induction of the expression and phosphorylation of STAT1. This triggers the transcription of many antiviral ISGs, but without the production of IFNs [67]. ISG15 is an IFN-induced ubiquitin-like protein with anti- or proviral functions depending on the context [68,69]. HEV infection has been demonstrated to induce ISG15 expression both in cell culture and pig models [70]. Interestingly, loss of ISG15 has no major effect on HEV replication but sensitized the response to IFN treatment. This is probably related to the enhanced expression of other general antiviral factors, including PKR, MX1, and OAS1 [70].

Inflammatory responses coordinated by the secretion of various cytokines and chemokines protects against infection, but dysregulation may cause serious pathogenesis. The production of inflammatory cytokines upon HEV infection has been widely observed in cell culture [21], animal models [71,72], and patients [23,73]. In HEV-infected pregnant women compared with non-pregnant women, the levels of TNF- $\alpha$ , IL-6, and IFN- $\gamma$  are significantly higher [73]. This is in line with the observation that *ex vivo* culturing of PBMCs from acute hepatitis E patients without ALF produces more IFN- $\gamma$  and TNF- $\alpha$ , compared to that from patients who developed ALF [23]. Collective evidence has indicated a central role of TNF- $\alpha$  and the NF- $\kappa$ B pathway in HEV triggered inflammatory response. In cell culture,

TNF- $\alpha$  has been shown to moderately inhibit HEV replication. Interestingly, it can induce a subset of ISGs via the NF- $\kappa$ B cascade to synergize the anti-HEV effect of IFN- $\alpha$  [74].

#### 2.4. The Implications of Innate Immune Response in Patient Outcome and Therapeutic Development

Exposure to HEV in healthy individuals usually results in asymptomatic infection. This likely reflects a strong host immune response against the infection, but such mechanisms are difficult to be captured and studied in detail. In asymptomatic blood donors, the role of anti-HEV antibody development and clearance has been shown [75]. In an Egyptian cohort, cell-mediated immune response has been indicated in asymptomatic individuals [76]. In symptomatic acutely infected patients, it is apparent that the innate immunity essentially contributes to the self-limiting process.

During pregnancy, the maternal immune system is dramatically altered to protect the fetus, such as the expression level of cytokines are changed to mediate the immunological tolerance [77]. This has been proposed as a key mechanism causing severe outcomes upon HEV infection, while many details remain unknown [78]. Differences in the expression of TLRs, production of inflammatory cytokines, and the immune cell compartment have been observed comparing HEV infected pregnant women that developed ALF compared to those without ALF or the non-pregnant population. Speculatively, this dysregulation may favor the infection and concurrently cause more severe liver damage, resulting in ALF and even death. In organ transplant patients, the use of immunosuppressive medication has been widely recognized as the key mechanism and cause of chronic hepatitis E [79,80]. These drugs primarily target the adaptive immune cells, in particular T cells, to prevent organ rejection. However, they are also able to affect innate antiviral effectors, and this at least, in part, contributes to the development of chronic infection [81].

As a potent antiviral cytokine, IFN- $\alpha$  has been approved for treating chronic hepatitis B and C for decades. In cell culture [82] and animal models [83], IFN- $\alpha$  exerts substantial anti-HEV activities. In chronic hepatitis E patients, several retrospective case series and case reports have documented an efficacy, but this is often associated with severe adverse events, including graft rejection and thrombocytopenia [82,84–87]. Nevertheless, understanding the anti-HEV mechanisms of IFN response will open new scenarios for developing more specific antiviral strategies. For instance, a number of MDA5 or RIG-I agonists are at various phases of preclinical or clinical development for treating viral infections [88]. These agents may exert more potent but specific antiviral efficacy alleviating the concerns of side effects.

### 3. Viral Strategies to Counteract Innate Immune Response

Despite the robust host response to HEV infection, the virus has developed many strategies to counteract and evade the defense mechanisms. Current knowledge mainly deciphers the interactions between HEV viral proteins with the host innate immunity.

ORF1 encodes a non-structural polyprotein, including several functional regions (Met, Y, PCP, HVR, X, Hel, and RdRp), which are essential for HEV replication. ORF1 has been shown to inhibit IFN- $\beta$  expression induced by poly (I:C) transfection in cell culture [89]. This is mainly attributed to the Papain-like cysteine protease domain (PCP) and macro domain (X) that are responsible for inhibiting the activation of RIG-I and TBK-1 as well as the phosphorylation of IRF3 (Figure 1) [89]. The cooperation of methyltransferase (Met) and PCP has been shown to inhibit the ISRE promoter activity and the expression of ISGs through inhibiting nuclear translocation and phosphorylation of STAT1 [90]. Interestingly, the X domain is able to inhibit the secretion of ferritin in cell culture [91]. As an acute-phase protein, ferritin is abundantly secreted in HEV infected patients associated with inflammatory response. Thus, the X domain has been proposed to attenuate host immune response by preventing ferritin secretion [91]. Finally, the RNA-dependent RNA polymerase (RdRp) domain has been reported to interact with miRNA to facilitate HEV replication [92].

ORF2 encodes the capsid protein, which binds 5' end of the genome, and is involved in viral encapsidation [93]. Three forms have been identified, including the infectious, glycosylated, and

cleaved ORF2 [94]. However, only the infectious ORF2 is assembled into viral particles [94] and mediates entry [95]. ORF2 has been shown to inhibit NF- $\kappa$ B activity by inhibiting I $\kappa$ B $\alpha$  ubiquitination (Figure 1) [96]. The host transmembrane protein 134 (TMEM134) interacts with ORF2 to attenuate its inhibitory effect on NF- $\kappa$ B by ORF2 [97]. ORF2 can also impair the host's apoptotic response to favor HEV infection [98].

ORF3 as a multifunctional protein has been proposed to create a favorable environment for HEV infection and pathogenesis [99–101]. In respect to the regulatory effects on innate immunity, it has been shown to inhibit STAT1 phosphorylation and ISG expression upon HEV infection (Figure 1) [102]. ORF3 of genotype 1 has been reported to downregulate the expression of tumor necrosis factor receptor 1-associated death domain protein (TRADD) and receptor-interacting protein kinase 1 (RIP1), thus inhibiting TLR3 mediated activation of NF- $\kappa$ B upon poly (I:C) treatment [103]. In line with this, ORF3 inhibits the expression of endogenous IFN $\alpha$ / $\beta$  through inhibiting the expression of TLR3 and TLR7 [99]. ORF3 also inhibits LPS-induced cytokines and chemotactic factors [56]. It has been further demonstrated that ORF3 inhibits the activation of NF- $\kappa$ B JAK-STAT and JNK-MAPK pathways induced by TNF $\alpha$ , IFN- $\gamma$ , and Anisomycin, respectively [99]. Counterintuitively, another study has demonstrated that ORF3 enhances IFN production upon poly (I:C) treatment through increased activation of RIG-I in a genotype-dependent manner [22]. Overall, ORF3 has been widely demonstrated to inhibit IFN and inflammatory responses to shape a favorable cellular environment for HEV infection.

Recently, ORF4 has been found in genotype 1 HEV. It has been reported to interact with RdRp to facilitate HEV replication [104], but whether and how ORF4 regulates host immune response remains unknown and deserves to be explored.

#### 4. Conclusion and Perspectives

A growing body of evidence has revealed the active interactions between the host innate immunity and HEV infection. Upon infection, a spectrum of receptors and/or sensors are able to sense HEV to induce IFN and inflammatory responses. This essentially establishes the antiviral states, but dysregulation may cause serious pathogenesis, such as in pregnant women and organ transplant patients. In turn, HEV has developed sophisticated strategies to counteract the host innate immune response, mainly through the interactions with the viral proteins. Thus, the interplay between host immunity and the virus eventually deters the infection course and decides the clinical outcome.

There remain several knowledge gaps to be further investigated. Firstly, the exact receptors/sensors that recognize HEV and the subsequent cascades in initiating responses are not fully clear yet. Secondly, the mechanisms of how the dysregulation of immune and inflammatory responses causes pathogenesis remains largely elusive. Moreover, the clinical relevance of many observations coming from the overexpression of viral proteins in different cell systems remains to be established. Further understanding these insights shall help to reveal the detailed mechanisms of causing hepatic and extra-hepatic diseases, and to devise therapeutic and interventional strategies to combat HEV infection.

**Funding:** This article is supported by the China Scholarship Council for funding PhD fellowships to Y. Li (No. 201703250073), C. Qu (No. 201509110121), P. Yu (No. 201708620178), and X. Ou (No. 201706910003)

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

1. Debing, Y.; Moradpour, D.; Neyts, J.; Gouttenoire, J. Update on hepatitis E virology: Implications for clinical practice. *J. Hepatol.* **2016**, *65*, 200–212. [[CrossRef](#)] [[PubMed](#)]
2. Melgaco, J.G.; Gardinali, N.R.; de Mello, V.D.M.; Leal, M.; Lewis-Ximenez, L.L.; Pinto, M.A. Hepatitis E: Update on prevention and control. *Biomed. Res. Int.* **2018**, *2018*, 5769201. [[CrossRef](#)] [[PubMed](#)]

3. Sehgal, R.; Patra, S.; David, P.; Vyas, A.; Khanam, A.; Hissar, S.; Gupta, E.; Kumar, G.; Kottlilil, S.; Maiwall, R.; et al. Impaired monocyte-macrophage functions and defective toll-like receptor signaling in hepatitis E virus-infected pregnant women with acute liver failure. *Hepatology* **2015**, *62*, 1683–1696. [[CrossRef](#)] [[PubMed](#)]
4. Beniwal, M.; Kumar, A.; Kar, P.; Jilani, N.; Sharma, J.B. Prevalence and severity of acute viral hepatitis and fulminant hepatitis during pregnancy: A prospective study from North India. *Indian J. Med. Microbiol.* **2003**, *21*, 184–185. [[PubMed](#)]
5. Kamar, N.; Selves, J.; Mansuy, J.M.; Ouezzani, L.; Peron, J.M.; Guitard, J.; Cointault, O.; Esposito, L.; Abravanel, F.; Danjoux, M.; et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N. Engl. J. Med.* **2008**, *358*, 811–817. [[CrossRef](#)] [[PubMed](#)]
6. Zhou, X.; de Man, R.A.; de Knecht, R.J.; Metselaar, H.J.; Peppelenbosch, M.P.; Pan, Q. Epidemiology and management of chronic Hepatitis E infection in solid organ transplantation: A comprehensive literature review. *Rev. Med. Virol.* **2013**, *23*, 295–304. [[CrossRef](#)] [[PubMed](#)]
7. Wang, Y.; Chen, G.; Pan, Q.; Zhao, J. Chronic Hepatitis E in a renal transplant recipient: The first report of genotype 4 hepatitis E virus caused chronic infection in organ recipient. *Gastroenterology* **2018**, *154*, 1199–1201. [[CrossRef](#)] [[PubMed](#)]
8. Hakim, M.S.; Ikram, A.; Zhou, J.; Wang, W.; Peppelenbosch, M.P.; Pan, Q. Immunity against hepatitis E virus infection: Implications for therapy and vaccine development. *Rev. Med. Virol.* **2018**, *28*. [[CrossRef](#)] [[PubMed](#)]
9. Wang, W.; Xu, L.; Su, J.; Peppelenbosch, M.P.; Pan, Q. Transcriptional regulation of antiviral interferon-stimulated genes. *Trends Microbiol.* **2017**, *25*, 573–584. [[CrossRef](#)]
10. Xu, L.; Wang, W.; Peppelenbosch, M.P.; Pan, Q. Noncanonical antiviral mechanisms of ISGS: Dispensability of inducible interferons. *Trends Immunol.* **2017**, *38*, 1–2. [[CrossRef](#)]
11. Janeway, C.A., Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb. Symp. Quant. Biol.* **1989**, *54 Pt. 1*, 1–13. [[CrossRef](#)]
12. Medzhitov, R. Toll-like receptors and innate immunity. *Nat. Rev. Immunol.* **2001**, *1*, 135–145. [[CrossRef](#)] [[PubMed](#)]
13. Alexopoulou, L.; Holt, A.C.; Medzhitov, R.; Flavell, R.A. Recognition of double-stranded RNA and activation of NF-Kappab by toll-like receptor 3. *Nature* **2001**, *413*, 732–738. [[CrossRef](#)] [[PubMed](#)]
14. Honda, K.; Ohba, Y.; Yanai, H.; Negishi, H.; Mizutani, T.; Takaoka, A.; Taya, C.; Taniguchi, T. Spatiotemporal regulation of myd88-irf-7 signalling for robust type-I interferon induction. *Nature* **2005**, *434*, 1035–1040. [[CrossRef](#)] [[PubMed](#)]
15. Xagorari, A.; Chlichlia, K. Toll-like receptors and viruses: Induction of innate antiviral immune responses. *Open Microbiol. J.* **2008**, *2*, 49–59. [[CrossRef](#)]
16. Li, K.; Li, N.L.; Wei, D.; Pfeffer, S.R.; Fan, M.; Pfeffer, L.M. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. *Hepatology* **2012**, *55*, 666–675. [[CrossRef](#)] [[PubMed](#)]
17. Negash, A.A.; Ramos, H.J.; Crochet, N.; Lau, D.T.; Doehle, B.; Papic, N.; Delker, D.A.; Jo, J.; Bertoletti, A.; Hagedorn, C.H.; et al. Il-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. *PLoS Pathog.* **2013**, *9*, e1003330. [[CrossRef](#)]
18. Real, C.I.; Lu, M.; Liu, J.; Huang, X.; Trippler, M.; Hossbach, M.; Deckert, J.; Jahn-Hofmann, K.; Ickenstein, L.M.; John, M.J.; et al. Hepatitis b virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. *Sci. Rep.* **2016**, *6*, 24865. [[CrossRef](#)]
19. Sepehri, Z.; Kiani, Z.; Alavian, S.M.; Arababadi, M.K.; Kennedy, D. The link between TLR7 signaling and hepatitis B virus infection. *Life Sci.* **2016**, *158*, 63–69. [[CrossRef](#)]
20. Devhare, P.B.; Desai, S.; Lole, K.S. Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies. *Sci. Rep.* **2016**, *6*, 26827. [[CrossRef](#)]
21. Devhare, P.B.; Chatterjee, S.N.; Arankalle, V.A.; Lole, K.S. Analysis of antiviral response in human epithelial cells infected with hepatitis E virus. *PLoS ONE* **2013**, *8*, e63793. [[CrossRef](#)]
22. Nan, Y.; Ma, Z.; Wang, R.; Yu, Y.; Kannan, H.; Fredericksen, B.; Zhang, Y.J. Enhancement of interferon induction by ORF3 product of hepatitis E virus. *J. Virol.* **2014**, *88*, 8696–8705. [[CrossRef](#)] [[PubMed](#)]
23. Majumdar, M.; Ratho, R.K.; Chawla, Y.; Singh, M.P. Role of tlr gene expression and cytokine profiling in the immunopathogenesis of viral hepatitis E. *J. Clin. Virol.* **2015**, *73*, 8–13. [[CrossRef](#)] [[PubMed](#)]

24. Kato, H.; Takeuchi, O.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Matsui, K.; Uematsu, S.; Jung, A.; Kawai, T.; Ishii, K.J.; et al. Differential roles of mda5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **2006**, *441*, 101–105. [[CrossRef](#)] [[PubMed](#)]
25. Satoh, T.; Kato, H.; Kumagai, Y.; Yoneyama, M.; Sato, S.; Matsushita, K.; Tsujimura, T.; Fujita, T.; Akira, S.; Takeuchi, O. Lgp2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 1512–1517. [[CrossRef](#)] [[PubMed](#)]
26. Kato, H.; Takeuchi, O.; Mikamo-Satoh, E.; Hirai, R.; Kawai, T.; Matsushita, K.; Hiiragi, A.; Dermody, T.S.; Fujita, T.; Akira, S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-i and melanoma differentiation-associated gene 5. *J. Exp. Med.* **2008**, *205*, 1601–1610. [[CrossRef](#)] [[PubMed](#)]
27. Kawai, T.; Takahashi, K.; Sato, S.; Coban, C.; Kumar, H.; Kato, H.; Ishii, K.J.; Takeuchi, O.; Akira, S. IPS-1, an adaptor triggering RIG-I- and MDA5-mediated type I interferon induction. *Nat. Immunol.* **2005**, *6*, 981–988. [[CrossRef](#)] [[PubMed](#)]
28. Seth, R.B.; Sun, L.; Ea, C.K.; Chen, Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF- $\kappa$ B and IRF 3. *Cell* **2005**, *122*, 669–682. [[CrossRef](#)] [[PubMed](#)]
29. Xu, L.G.; Wang, Y.Y.; Han, K.J.; Li, L.Y.; Zhai, Z.; Shu, H.B. VISA is an adapter protein required for virus-triggered IFN- $\beta$  signaling. *Mol. Cell* **2005**, *19*, 727–740. [[CrossRef](#)]
30. Meylan, E.; Curran, J.; Hofmann, K.; Moradpour, D.; Binder, M.; Bartenschlager, R.; Tschopp, J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* **2005**, *437*, 1167–1172. [[CrossRef](#)]
31. Lu, H.L.; Liao, F. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. *J. Immunol.* **2013**, *191*, 3264–3276. [[CrossRef](#)] [[PubMed](#)]
32. Sato, S.; Li, K.; Kameyama, T.; Hayashi, T.; Ishida, Y.; Murakami, S.; Watanabe, T.; Iijima, S.; Sakurai, Y.; Watashi, K.; et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. *Immunity* **2015**, *42*, 123–132. [[CrossRef](#)] [[PubMed](#)]
33. Saito, T.; Owen, D.M.; Jiang, F.; Marcotrigiano, J.; Gale, M., Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature* **2008**, *454*, 523–527. [[CrossRef](#)] [[PubMed](#)]
34. Cao, X.; Ding, Q.; Lu, J.; Tao, W.; Huang, B.; Zhao, Y.; Niu, J.; Liu, Y.J.; Zhong, J. MDA5 plays a critical role in interferon response during hepatitis C virus infection. *J. Hepatol.* **2015**, *62*, 771–778. [[CrossRef](#)] [[PubMed](#)]
35. Du, X.; Pan, T.; Xu, J.; Zhang, Y.; Song, W.; Yi, Z.; Yuan, Z. Hepatitis C virus replicative double-stranded RNA is a potent interferon inducer that triggers interferon production through MDA5. *J. Gen. Virol.* **2016**, *97*, 2868–2882. [[CrossRef](#)] [[PubMed](#)]
36. Jagya, N.; Varma, S.P.; Thakral, D.; Joshi, P.; Durgapal, H.; Panda, S.K. RNA-seq based transcriptome analysis of hepatitis E virus (HEV) and hepatitis B virus (HBV) replicon transfected HUH-7 cells. *PLoS ONE* **2014**, *9*, e87835. [[CrossRef](#)] [[PubMed](#)]
37. Wang, W.; Wang, Y.; Qu, C.; Wang, S.; Zhou, J.; Cao, W.; Xu, L.; Ma, B.; Hakim, M.S.; Yin, Y.; et al. The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. *Hepatology* **2018**, *67*, 2096–2112. [[CrossRef](#)] [[PubMed](#)]
38. Kamar, N.; Bendall, R.P.; Peron, J.M.; Cintas, P.; Prudhomme, L.; Mansuy, J.M.; Rostaing, L.; Keane, F.; Ijaz, S.; Izopet, J.; et al. Hepatitis E virus and neurologic disorders. *Emerg. Infect. Dis.* **2011**, *17*, 173–179. [[CrossRef](#)] [[PubMed](#)]
39. Cheung, M.C.; Maguire, J.; Carey, I.; Wendon, J.; Agarwal, K. Review of the neurological manifestations of hepatitis E infection. *Ann. Hepatol.* **2012**, *11*, 618–622.
40. Wang, Y.; Wang, S.; Wu, J.; Jiang, Y.; Zhang, H.; Li, S.; Liu, H.; Yang, C.; Tang, H.; Guo, N.; et al. Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. *EBioMedicine* **2018**, *36*, 122–130. [[CrossRef](#)]
41. Kamar, N.; Mansuy, J.M.; Esposito, L.; Legrand-Abravanel, F.; Peron, J.M.; Durand, D.; Rostaing, L.; Izopet, J. Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. *Am. J. Kidney Dis.* **2005**, *45*, 193–196. [[CrossRef](#)] [[PubMed](#)]
42. Sinha, S.; Jha, R.; Lakhtakia, S.; Narayan, G. Acute pancreatitis following kidney transplantation - role of viral infections. *Clin. Transplant.* **2003**, *17*, 32–36. [[CrossRef](#)] [[PubMed](#)]



43. Deniel, C.; Coton, T.; Brardjianian, S.; Guisset, M.; Nicand, E.; Simon, F. Acute pancreatitis: A rare complication of acute hepatitis E. *J. Clin. Virol* **2011**, *51*, 202–204. [[CrossRef](#)] [[PubMed](#)]
44. Zhou, X.; Huang, F.; Xu, L.; Lin, Z.; de Vrij, F.M.S.; Ayo-Martin, A.C.; van der Kroeg, M.; Zhao, M.; Yin, Y.; Wang, W.; et al. Hepatitis E virus infects neurons and brains. *J. Infect. Dis.* **2017**, *215*, 1197–1206. [[CrossRef](#)] [[PubMed](#)]
45. Tian, J.; Shi, R.; Liu, T.; She, R.; Wu, Q.; An, J.; Hao, W.; Soomro, M.H. Brain infection by hepatitis E virus probably via damage of the blood-brain barrier due to alterations of tight junction proteins. *Front. Cell Infect. Microbiol.* **2019**, *9*, 52. [[CrossRef](#)]
46. Huang, F.; Yang, C.; Zhou, X.; Yu, W.; Pan, Q. Rhesus macaques persistently infected with hepatitis E shed virus into Urine. *J. Hepatol.* **2016**, *64*, 1446–1447. [[CrossRef](#)]
47. Gouilly, J.; Chen, Q.; Siewiera, J.; Cartron, G.; Levy, C.; Dubois, M.; Al-Daccak, R.; Izopet, J.; Jabrane-Ferrat, N.; El Costa, H. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. *Nat. Commun.* **2018**, *9*, 4748. [[CrossRef](#)]
48. Rouse, B.T.; Sehrawat, S. Immunity and immunopathology to viruses: What decides the outcome? *Nat. Rev. Immunol.* **2010**, *10*, 514–526. [[CrossRef](#)]
49. Cooper, M.A.; Fehniger, T.A.; Turner, S.C.; Chen, K.S.; Ghaheri, B.A.; Ghayur, T.; Carson, W.E.; Caligiuri, M.A. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. *Blood* **2001**, *97*, 3146–3151. [[CrossRef](#)]
50. Racanelli, V.; Rehermann, B. The liver as an immunological organ. *Hepatology* **2006**, *43*, S54–S62. [[CrossRef](#)]
51. Rehermann, B.; Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat. Rev. Immunol.* **2005**, *5*, 215–229. [[CrossRef](#)] [[PubMed](#)]
52. Ahmad, A.; Alvarez, F. Role of nk and nkt cells in the immunopathogenesis of HCV-induced hepatitis. *J. Leukoc. Biol.* **2004**, *76*, 743–759. [[CrossRef](#)] [[PubMed](#)]
53. Srivastava, R.; Aggarwal, R.; Jameel, S.; Puri, P.; Gupta, V.K.; Ramesh, V.S.; Bhatia, S.; Naik, S. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. *Viral. Immunol.* **2007**, *20*, 56–65. [[CrossRef](#)] [[PubMed](#)]
54. Srivastava, R.; Aggarwal, R.; Bhagat, M.R.; Chowdhury, A.; Naik, S. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E. *J. Viral. Hepat.* **2008**, *15*, 910–916. [[CrossRef](#)] [[PubMed](#)]
55. Baley, J.E.; Schacter, B.Z. Mechanisms of diminished natural killer cell activity in pregnant women and neonates. *J. Immunol.* **1985**, *134*, 3042–3048. [[PubMed](#)]
56. Prabhu, S.B.; Gupta, P.; Durgapal, H.; Rath, S.; Gupta, S.D.; Acharya, S.K.; Panda, S.K. Study of cellular immune response against hepatitis E virus (HEV). *J. Viral. Hepat.* **2011**, *18*, 587–594. [[CrossRef](#)] [[PubMed](#)]
57. Abravanel, F.; Barrague, H.; Dorr, G.; Saune, K.; Peron, J.M.; Alric, L.; Kamar, N.; Izopet, J.; Champagne, E. Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. *J. Infect.* **2016**, *72*, 723–730. [[CrossRef](#)] [[PubMed](#)]
58. Clausen, J.; Vergeiner, B.; Enk, M.; Petzer, A.L.; Gastl, G.; Gunsilius, E. Functional significance of the activation-associated receptors CD25 and CD69 on human nk-cells and NK-like T-cells. *Immunobiology* **2003**, *207*, 85–93. [[CrossRef](#)] [[PubMed](#)]
59. Liu, T.; Xiao, P.; Li, R.; She, R.; Tian, J.; Wang, J.; Mao, J.; Yin, J.; Shi, R. Increased mast cell activation in mongolian gerbils infected by hepatitis E virus. *Front. Microbiol.* **2018**, *9*, 2226. [[CrossRef](#)] [[PubMed](#)]
60. Mesev, E.V.; LeDesma, R.A.; Ploss, A. Decoding type i and iii interferon signalling during viral infection. *Nat. Microbiol.* **2019**. [[CrossRef](#)] [[PubMed](#)]
61. Ivashkiv, L.B.; Donlin, L.T. Regulation of type i interferon responses. *Nat. Rev. Immunol.* **2014**, *14*, 36–49. [[CrossRef](#)] [[PubMed](#)]
62. Schoggins, J.W.; Wilson, S.J.; Panis, M.; Murphy, M.Y.; Jones, C.T.; Bieniasz, P.; Rice, C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* **2011**, *472*, 481–485. [[CrossRef](#)] [[PubMed](#)]
63. Wang, W.; Yin, Y.; Xu, L.; Su, J.; Huang, F.; Wang, Y.; Boor, P.P.C.; Chen, K.; Wang, W.; Cao, W.; et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. *Sci. Signal.* **2017**, *10*. [[CrossRef](#)] [[PubMed](#)]
64. Yin, X.; Li, X.; Ambardekar, C.; Hu, Z.; Lhomme, S.; Feng, Z. Hepatitis E virus persists in the presence of a type iii interferon response. *PLoS Pathog.* **2017**, *13*, e1006417. [[CrossRef](#)] [[PubMed](#)]

65. Takahashi, M.; Tanaka, T.; Takahashi, H.; Hoshino, Y.; Nagashima, S.; Jirintai; Mizuo, H.; Yazaki, Y.; Takagi, T.; Azuma, M.; et al. Hepatitis E virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: Characterization of hev virions in blood circulation. *J. Clin. Microbiol.* **2010**, *48*, 1112–1125. [[PubMed](#)]
66. Xu, L.; Wang, W.; Li, Y.; Zhou, X.; Yin, Y.; Wang, Y.; de Man, R.A.; van der Laan, L.J.W.; Huang, F.; Kamar, N.; et al. Rig-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. *Hepatology* **2017**, *65*, 1823–1839. [[CrossRef](#)]
67. Xu, L.; Zhou, X.; Wang, W.; Wang, Y.; Yin, Y.; Laan, L.J.; Sprengers, D.; Metselaar, H.J.; Peppelenbosch, M.P.; Pan, Q. IFN regulatory factor 1 restricts hepatitis E virus replication by activating stat1 to induce antiviral ifn-stimulated genes. *Faseb J.* **2016**, *30*, 3352–3367. [[CrossRef](#)]
68. Hsiang, T.Y.; Zhao, C.; Krug, R.M. Interferon-induced isg15 conjugation inhibits influenza A virus gene expression and replication in human cells. *J. Virol.* **2009**, *83*, 5971–5977. [[CrossRef](#)]
69. Broering, R.; Zhang, X.; Kottlilil, S.; Trippler, M.; Jiang, M.; Lu, M.; Gerken, G.; Schlaak, J.F. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the ifn response. *Gut* **2010**, *59*, 1111–1119. [[CrossRef](#)]
70. Sooryanarain, H.; Rogers, A.J.; Cao, D.; Haac, M.E.R.; Karpe, Y.A.; Meng, X.J. ISG15 modulates type I interferon signaling and the antiviral response during hepatitis E virus replication. *J. Virol.* **2017**, *91*. [[CrossRef](#)]
71. Cao, D.; Cao, Q.M.; Subramaniam, S.; Yugo, D.M.; Heffron, C.L.; Rogers, A.J.; Kenney, S.P.; Tian, D.; Matzinger, S.R.; Overend, C.; et al. Pig model mimicking chronic hepatitis E virus infection in immunocompromised patients to assess immune correlates during chronicity. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 6914–6923. [[CrossRef](#)] [[PubMed](#)]
72. Ahn, H.S.; Han, S.H.; Kim, Y.H.; Park, B.J.; Kim, D.H.; Lee, J.B.; Park, S.Y.; Song, C.S.; Lee, S.W.; Choi, C.; et al. Adverse fetal outcomes in pregnant rabbits experimentally infected with rabbit hepatitis E virus. *Virology* **2017**, *512*, 187–193. [[CrossRef](#)] [[PubMed](#)]
73. Kumar, A.; Devi, S.G.; Kar, P.; Agarwal, S.; Husain, S.A.; Gupta, R.K.; Sharma, S. Association of cytokines in hepatitis E with pregnancy outcome. *Cytokine* **2014**, *65*, 95–104. [[CrossRef](#)] [[PubMed](#)]
74. Wang, W.; Xu, L.; Brandsma, J.H.; Wang, Y.; Hakim, M.S.; Zhou, X.; Yin, Y.; Fuhler, G.M.; van der Laan, L.J.; van der Woude, C.J.; et al. Convergent transcription of interferon-stimulated genes by tnf-alpha and ifn-alpha augments antiviral activity against hcv and hev. *Sci. Rep.* **2016**, *6*, 25482. [[CrossRef](#)] [[PubMed](#)]
75. Kraef, C.; Schlein, C.; Hiller, J.; Westholter, D.; Denzer, U.; Horvatits, T.; Peine, S.; Lohse, A.W.; Lutgehetmann, M.; Polywka, S.; et al. Course of hev viremia and anti-HEV igm/igg response in asymptomatic blood donors. *J. Clin. Virol.* **2018**, *105*, 26–30. [[CrossRef](#)] [[PubMed](#)]
76. Eldin, S.S.; Seddik, I.; Daef, E.A.; Shata, M.T.; Raafat, M.; Abdel Baky, L.; Nafeh, M.A. Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in assiut, Egypt. *Egypt J. Immunol.* **2010**, *17*, 73–86.
77. Pal, R.; Aggarwal, R.; Naik, S.R.; Das, V.; Das, S.; Naik, S. Immunological alterations in pregnant women with acute hepatitis E. *J. Gastroenterol. Hepatol.* **2005**, *20*, 1094–1101. [[CrossRef](#)]
78. Navaneethan, U.; Al Mohajer, M.; Shata, M.T. Hepatitis E and pregnancy: Understanding the pathogenesis. *Liver Int.* **2008**, *28*, 1190–1199. [[CrossRef](#)]
79. Wang, Y.; Zhou, X.; Debing, Y.; Chen, K.; van Der Laan, L.J.; Neyts, J.; Janssen, H.L.; Metselaar, H.J.; Peppelenbosch, M.P.; Pan, Q. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. *Gastroenterology* **2014**, *146*, 1775–1783. [[CrossRef](#)]
80. Zhou, X.; Wang, Y.; Metselaar, H.J.; Janssen, H.L.; Peppelenbosch, M.P.; Pan, Q. Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mtor pathway. *J. Hepatol.* **2014**, *61*, 746–754. [[CrossRef](#)]
81. Wang, Y.; Metselaar, H.J.; Peppelenbosch, M.P.; Pan, Q. Chronic hepatitis E in solid-organ transplantation: The key implications of immunosuppressants. *Curr. Opin. Infect. Dis.* **2014**, *27*, 303–308. [[CrossRef](#)] [[PubMed](#)]
82. Zhou, X.; Xu, L.; Wang, W.; Watashi, K.; Wang, Y.; Sprengers, D.; de Ruyter, P.E.; van der Laan, L.J.; Metselaar, H.J.; Kamar, N.; et al. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. *J. Viral. Hepat.* **2016**, *23*, 294–304. [[CrossRef](#)] [[PubMed](#)]

83. Van de Garde, M.D.B.; Pas, S.D.; van Oord, G.W.; Gama, L.; Choi, Y.; de Man, R.A.; Boonstra, A.; Vanwolleghem, T. Interferon-alpha treatment rapidly clears hepatitis E virus infection in humanized mice. *Sci. Rep.* **2017**, *7*, 8267. [[CrossRef](#)] [[PubMed](#)]
84. Peters van Ton, A.M.; Gevers, T.J.; Drenth, J.P. Antiviral therapy in chronic hepatitis E: A systematic review. *J. Viral. Hepat.* **2015**, *22*, 965–973. [[CrossRef](#)] [[PubMed](#)]
85. Haagsma, E.B.; Riezebos-Brilman, A.; van den Berg, A.P.; Porte, R.J.; Niesters, H.G. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon Alpha-2B. *Liver Transpl.* **2010**, *16*, 474–477. [[CrossRef](#)] [[PubMed](#)]
86. Kamar, N.; Abravanel, F.; Garrouste, C.; Cardeau-Desangles, I.; Mansuy, J.M.; Weclawiak, H.; Izopet, J.; Rostaing, L. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. *Nephrol. Dial. Transplant.* **2010**, *25*, 2792–2795. [[CrossRef](#)] [[PubMed](#)]
87. Kamar, N.; Rostaing, L.; Abravanel, F.; Garrouste, C.; Esposito, L.; Cardeau-Desangles, I.; Mansuy, J.M.; Selves, J.; Peron, J.M.; Otal, P.; et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. *Clin. Infect. Dis.* **2010**, *50*, e30–e33. [[CrossRef](#)] [[PubMed](#)]
88. Kasumba, D.M.; Grandvaux, N. Therapeutic targeting of rig-i and mda5 might not lead to the same rome. *Trends Pharmacol. Sci.* **2019**, *40*, 116–127. [[CrossRef](#)]
89. Nan, Y.; Yu, Y.; Ma, Z.; Khattar, S.K.; Fredericksen, B.; Zhang, Y.J. Hepatitis E virus inhibits type I interferon induction by ORF1 products. *J. Virol.* **2014**, *88*, 11924–11932. [[CrossRef](#)]
90. Bagdassarian, E.; Doceul, V.; Pellerin, M.; Demange, A.; Meyer, L.; Jouvenet, N.; Pavio, N. The amino-terminal region of hepatitis E virus orf1 containing a methyltransferase (Met) and a papain-like cysteine protease (PCP) domain counteracts type i interferon response. *Viruses* **2018**, *10*. [[CrossRef](#)]
91. Ojha, N.K.; Lole, K.S. Hepatitis E virus orf1 encoded macro domain protein interacts with light chain subunit of human ferritin and inhibits its secretion. *Mol. Cell Biochem.* **2016**, *417*, 75–85. [[CrossRef](#)] [[PubMed](#)]
92. Haldipur, B.; Bhukya, P.L.; Arankalle, V.; Lole, K. Positive regulation of hepatitis E virus replication by microRNA-122. *J. Virol.* **2018**, *92*. [[CrossRef](#)] [[PubMed](#)]
93. Gu, Y.; Zhang, J.; Wang, Y.B.; Li, S.W.; Yang, H.J.; Luo, W.X.; Xia, N.S. Selection of a peptide mimic the neutralization epitope of hepatitis E virus with phage peptide display technology. *Sheng Wu Gong Cheng Xue Bao* **2003**, *19*, 680–685. [[PubMed](#)]
94. Montpellier, C.; Wychowski, C.; Sayed, I.M.; Meunier, J.C.; Saliou, J.M.; Ankavay, M.; Bull, A.; Pillez, A.; Abravanel, F.; Helle, F.; et al. Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein. *Gastroenterology* **2018**, *154*, 211–223 e218. [[CrossRef](#)] [[PubMed](#)]
95. Kalia, M.; Chandra, V.; Rahman, S.A.; Sehgal, D.; Jameel, S. Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection. *J. Virol.* **2009**, *83*, 12714–12724. [[CrossRef](#)] [[PubMed](#)]
96. Surjit, M.; Varshney, B.; Lal, S.K. The orf2 glycoprotein of hepatitis E virus inhibits cellular nf-kappab activity by blocking ubiquitination mediated proteasomal degradation of ikappabalpha in human hepatoma cells. *BMC Biochem* **2012**, *13*, 7. [[CrossRef](#)] [[PubMed](#)]
97. Tian, Y.; Huang, W.; Yang, J.; Wen, Z.; Geng, Y.; Zhao, C.; Zhang, H.; Wang, Y. Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-Kappab pathway. *Virus Res.* **2017**, *228*, 102–108. [[CrossRef](#)] [[PubMed](#)]
98. John, L.; Thomas, S.; Herchenroder, O.; Putzer, B.M.; Schaefer, S. Hepatitis E virus ORF2 protein activates the pro-apoptotic gene chop and anti-apoptotic heat shock proteins. *PLoS ONE* **2011**, *6*, e25378. [[CrossRef](#)]
99. Lei, Q.; Li, L.; Zhang, S.; Li, T.; Zhang, X.; Ding, X.; Qin, B. Hev orf3 downregulates tlr7 to inhibit the generation of type i interferon via impairment of multiple signaling pathways. *Sci. Rep.* **2018**, *8*, 8585. [[CrossRef](#)]
100. Ding, Q.; Heller, B.; Capuccino, J.M.; Song, B.; Nimgaonkar, I.; Hrebikova, G.; Contreras, J.E.; Ploss, A. Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 1147–1152. [[CrossRef](#)]
101. Chandra, V.; Kalia, M.; Hajela, K.; Jameel, S. The orf3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the CBL-CIN85 complex. *J. Virol.* **2010**, *84*, 3857–3867. [[CrossRef](#)] [[PubMed](#)]
102. Dong, C.; Zafrullah, M.; Mixson-Hayden, T.; Dai, X.; Liang, J.; Meng, J.; Kamili, S. Suppression of interferon-alpha signaling by hepatitis E virus. *Hepatology* **2012**, *55*, 1324–1332. [[CrossRef](#)] [[PubMed](#)]

103. He, M.; Wang, M.; Huang, Y.; Peng, W.; Zheng, Z.; Xia, N.; Xu, J.; Tian, D. The orf3 protein of genotype 1 hepatitis E virus suppresses TLR3-induced NF-Kappab signaling via tradd and RIP1. *Sci. Rep.* **2016**, *6*, 27597. [[CrossRef](#)] [[PubMed](#)]
104. Nair, V.P.; Anang, S.; Subramani, C.; Madhvi, A.; Bakshi, K.; Srivastava, A.; Shalimar; Nayak, B.; Ranjith Kumar, C.T.; Surjit, M. Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. *PLoS Pathog.* **2016**, *12*, e1005521. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).